跳至主要内容
临床试验/NCT02444169
NCT02444169已完成不适用

Retrospective Evaluation of Safety of Combination Treatment With the Ulthera® System and Xeomin, Belotero Balance, and Radiesse

Ulthera, Inc5 个研究点 分布在 1 个国家目标入组 101 人开始时间: 2015年4月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Ulthera, Inc
入组人数
101
试验地点
5
主要终点
Number of Participants with Adverse Events as a Measure of Safety and Tolerability

研究概览

简要总结

A retrospective study to evaluate the Ulthera® System for its potential interaction with toxins and fillers. Up to 500 subjects will be enrolled.

详细描述

This is a retrospective, multi-site study involving chart reviews of subjects who have received an Ultherapy treatment along with Radiesse®, Xeomin®, and/or Belotero® Balance within six months apart in the face and/or neck areas. Enrolled subjects will have received an Ultherapy treatment along with botulinum toxin A and/or filler treatment(s) within the last two years and with filler and toxin treatment occurring within 6 months before or after Ultherapy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
25 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female, age 25 to 70 years.
  • Subject in good health
  • Subject must have had an Ultherapy treatment and Merz branded neurotoxin/filler treatments within 6 months of one or more Ultherapy treatments.
  • Subject must have had both Ultherapy and neurotoxin/filler within the last 2 years (since April 2013) and with toxin/filler treatment within 6 months proximity to the Ultherapy treatment date.
  • Absence of physical or psychological conditions unacceptable to the investigator, especially those whom are contraindicated to receive treatments with Ultherapy, Belotero, Radiesse and/or Xeomin.
  • Subjects who are identified with good photography, must have the ability to be contacted to provide authorization to disclose photographs for usage of previously taken photography, if photos are deemed worthy of publication.

排除标准

  • Subjects who have had any and all Ultherapy treatment(s) before April
  • Subjects who have not received Radiesse®, Xeomin®, and/or Belotero Balance® within 6 months of Ultherapy treatment date.
  • Psychiatric drugs and/or diseases that in the investigators opinion would impair the subject from understanding the photo consent, if photos are chosen for publication.

结局指标

主要结局

Number of Participants with Adverse Events as a Measure of Safety and Tolerability

时间窗: Within 6 months before or after Ultherapy

An assessment of adverse events through chart review will evaluate the safety of combination treatments of Ultherapy with toxins/fillers.

次要结局

未报告次要终点

研究者

发起方
Ulthera, Inc
申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验